16th World ADC London Post Conference Presentation

New modalities, emerging targets, and novel payload technologies are transforming how developers approach targeted oncology therapeutics. In fact, novel ADC modalities grew by 72% year-on-year, signalling a major shift beyond traditional constructs.

To help drug developers, researchers, and strategic leaders navigate this evolving space, our analysts have compiled a data-driven overview of the ADC landscape, highlighting the technologies, pipeline activity, and emerging strategies shaping the next generation of ADCs.

Key Highlights from the Report

The Rise of Next-Generation ADC Modalities

• Discover how bispecific ADCs, dual-payload ADCs, and antibody-oligonucleotide conjugates are expanding the therapeutic possibilities of targeted drug delivery.

Pipeline & Clinical Development Trends

• Explore the growing ADC pipeline and see how new programs are progressing from discovery through clinical development.

Emerging Targets Driving Innovation

• Understand which targets are gaining momentum across ADC development and how developers are selecting antigens to improve therapeutic outcomes.

Payload Technology Advancements

• Learn how novel payload strategies and combinations are being used to improve potency and overcome resistance mechanisms.

Strategic Signals Across the Industry

• Identify where companies are investing, partnering, and advancing new ADC technologies.